vi-syneral inj.sol
ΜΙΝΕΡΒΑ ΦΑΡΜΑΚΕΥΤΙΚΗ Α.Ε. - ergocalciferol - ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ - ΔΙΑΛΥΜΑ ΕΝΕΣΙΜΟ ΜΙΚΡΟΥ ΟΓΚΟΥ (< 50 ml)
synercid (150+350)mg/vial pd.c.so.in
monarch pharmaceuticals ireland, dublin, ireland - quinupristin / dalfopristin - ΚΟΝΙΣ ΓΙΑ ΠΥΚΝΟ ΔΙΑΛΥΜΑ ΓΙΑ ΠΑΡΑΣΚΕΥΗ ΔΙΑΛΥΜΑΤΟΣ ΠΡΟΣ ΕΓΧΥΣΗ - (150+350)mg/vial - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ
synercid (180+420)mg/vial pd.c.so.in
monarch pharmaceuticals ireland, dublin, ireland - quinupristin / dalfopristin - ΚΟΝΙΣ ΓΙΑ ΠΥΚΝΟ ΔΙΑΛΥΜΑ ΓΙΑ ΠΑΡΑΣΚΕΥΗ ΔΙΑΛΥΜΑΤΟΣ ΠΡΟΣ ΕΓΧΥΣΗ - (180+420)mg/vial - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ
gallimune 407 nd + ib + eds + art emulsion for injection
merial sas (0000008553) 29 avenue tony garnier, lyon, 69007 - inactivated newcastle disease virus, ulster 2c strain; inactivated infectious bronchitis virus, mass 41 strain; inactivated egg drop syndrome virus (eds76), v127 strain; inactivated avian rhinotracheitis virus (swollen head syndrome), vco3 strain - emulsion for injection - inactivated newcastle disease virus, ulster 2c strain (8900000062) 50pd50; inactivated infectious bronchitis virus, mass 41 strain (8900000063) 18hi.u; inactivated egg drop syndrome virus (eds76), v127 strain (8900000064) 180hi.u; inactivated avian rhinotracheitis virus (swollen head syndrome), vco3 strain (8900000065) 60ip.u - avian infectious bronchitis virus + newcastle disease virus/ paramyxovirus + avian adenovirus + avian rhinotracheitis virus
syner-kinase 100.000 iu κονισ για διαλυμα προσ εγχυση
ΙΦΕΤ ΑΕ - urokinase - ΚΟΝΙΣ ΓΙΑ ΔΙΑΛΥΜΑ ΠΡΟΣ ΕΓΧΥΣΗ - 100.000 iu - 0009039536 - urokinase - 0.000000
pollisynergen 625mg/cap caps
honey style ltd - other therapeutic products - ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ - 625mg/cap - ΦΑΡΜΑΚΕΥΤΙΚΑ ΠΡΟΪΟΝΤΑ ΦΥΤΙΚΗΣ ΠΡΟΕΛΕΥΣΗΣ
vidaza
bristol-myers squibb pharma eeig - αζακιτιδίνη - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - Αντινεοπλασματικοί παράγοντες - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.
azacitidine celgene
celgene europe bv - αζακιτιδίνη - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - Αντινεοπλασματικοί παράγοντες - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.